
Chiara Pfanner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5731608/publications.pdf Version: 2024-02-01



<u> Chiada Deanned</u>

#	Article	IF	CITATIONS
1	An Exploratory Study of Emotional Dysregulation Dimensions in Youth With Attention Deficit Hyperactivity Disorder and/or Bipolar Spectrum Disorders. Frontiers in Psychiatry, 2021, 12, 619037.	2.6	9
2	Treatment with Methylphenidate Improves Affective but Not Cognitive Empathy in Youths with Attention-Deficit/Hyperactivity Disorder. Children, 2021, 8, 596.	1.5	5
3	Autism Spectrum Disorder and Disruptive Behavior Disorders Comorbidities Delineate Clinical Phenotypes in Attention-Deficit Hyperactivity Disorder: Novel Insights from the Assessment of Psychopathological and Neuropsychological Profiles. Journal of Clinical Medicine, 2020, 9, 3839.	2.4	13
4	The Role of Executive Functions in the Development of Empathy and Its Association with Externalizing Behaviors in Children with Neurodevelopmental Disorders and Other Psychiatric Comorbidities. Brain Sciences, 2020, 10, 489.	2.3	12
5	A Naturalistic Study of Youth Referred to a Tertiary Care Facility for Acute Hypomanic or Manic Episode. Brain Sciences, 2020, 10, 689.	2.3	4
6	Emotional dysregulation and callous unemotional traits as possible predictors of short-term response to methylphenidate monotherapy in drug-naÃ ⁻ ve youth with ADHD. Comprehensive Psychiatry, 2020, 100, 152178.	3.1	11
7	<p>Effects of melatonin in children with attention-deficit/hyperactivity disorder with sleep disorders after methylphenidate treatment</p> . Neuropsychiatric Disease and Treatment, 2019, Volume 15, 663-667.	2.2	19
8	A NATURALISTIC EXPLORATORY STUDY OF OBSESSIVE-COMPULSIVE BIPOLAR COMORBIDITY IN YOUTH. Journal of Affective Disorders, 2018, 231, 21-26.	4.1	17
9	A Naturalistic Comparison of Methylphenidate and Risperidone Monotherapy in Drug-Naive Youth With Attention-Deficit/Hyperactivity Disorder Comorbid With Oppositional Defiant Disorder and Aggression. Journal of Clinical Psychopharmacology, 2017, 37, 590-594.	1.4	20
10	Use of Quetiapine in Children and Adolescents. Paediatric Drugs, 2015, 17, 125-140.	3.1	25
11	Antipsychotic augmentation of selective serotonin reuptake inhibitors in resistant tic-related obsessive-compulsive disorder in children and adolescents: AÂnaturalistic comparative study. Journal of Psychiatric Research, 2013, 47, 1007-1012.	3.1	50
12	Quetiapine Monotherapy in Adolescents with Bipolar Disorder Comorbid with Conduct Disorder. Journal of Child and Adolescent Psychopharmacology, 2013, 23, 568-571.	1.3	14
13	Pediatric Generalized Anxiety Disorder. Journal of Clinical Psychopharmacology, 2013, 33, 577-579.	1.4	Ο
14	Pediatric Social Anxiety Disorder: Predictors of Response to Pharmacological Treatment. Journal of Child and Adolescent Psychopharmacology, 2012, 22, 410-414.	1.3	15
15	Aripiprazole in Children with Tourette's Disorder and Co-morbid Attention-Deficit/Hyperactivity Disorder: A 12-Week, Open-Label, Preliminary Study. Journal of Child and Adolescent Psychopharmacology, 2012, 22, 120-125.	1.3	28
16	Developmental Pathways for Different Subtypes of Early-Onset Bipolarity in Youths. Journal of Clinical Psychiatry, 2012, 73, 1335-1341.	2.2	24
17	Aripiprazole Augmentation in 39 Adolescents With Medication-Resistant Obsessive-Compulsive Disorder. Journal of Clinical Psychopharmacology, 2010, 30, 688-693.	1.4	49
18	A Naturalistic Exploratory Study of the Impact of Demographic, Phenotypic and Comorbid Features in Pediatric Obsessive-Compulsive Disorder. Psychopathology, 2010, 43, 69-78.	1.5	70

CHIARA PFANNER

#	Article	IF	CITATIONS
19	Pharmacological response in juvenile bipolar disorder subtypes: A naturalistic retrospective examination. Psychiatry Research, 2010, 177, 192-198.	3.3	34
20	Pharmacotherapy in Paediatric Obsessive-Compulsive Disorder. CNS Drugs, 2009, 23, 241-252.	5.9	42
21	P.4.c.001 Effectiveness of the combination of citalopram and clomipramine in resistant OCD patients. European Neuropsychopharmacology, 2008, 18, S492-S493.	0.7	0
22	Effectiveness of Long-Term Augmentation with Citalopram to Clomipramine in Treatment-Resistant OCD Patients. CNS Spectrums, 2008, 13, 971-976.	1.2	35
23	Bipolar Co-morbidity in Pediatric Obsessive-Compulsive Disorder: Clinical and Treatment Implications. Journal of Child and Adolescent Psychopharmacology, 2007, 17, 475-486.	1.3	28
24	Clinical and research implications of panic-bipolar comorbidity in children and adolescents. Psychiatry Research, 2007, 153, 47-54.	3.3	30
25	Clinical Implications of DSM-IV Subtyping of Bipolar Disorders in Referred Children and Adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 2007, 46, 1299-1306.	0.5	31
26	Developmental Differences According to Age at Onset in Juvenile Bipolar Disorder. Journal of Child and Adolescent Psychopharmacology, 2006, 16, 679-685.	1.3	44
27	Comorbidity of obsessive-compulsive disorder and attention-deficit/hyperactivity disorder in referred children and adolescents. Comprehensive Psychiatry, 2006, 47, 42-47.	3.1	90
28	Insight in Body Dysmorphic Disorder with and Without Comorbid Obsessive-Compulsive Disorder. CNS Spectrums, 2006, 11, 494-498.	1.2	19
29	Attention-deficit hyperactivity disorder – bipolar comorbidity in children and adolescents. Bipolar Disorders, 2006, 8, 373-381.	1.9	108
30	Augmentation strategy with olanzapine in resistant obsessive compulsive disorder: an Italian long-term open-label study. Journal of Psychopharmacology, 2005, 19, 392-394.	4.0	48
31	Kleptomania in impulse control disorders, obsessive-compulsive disorder, and bipolar spectrum disorder: Clinical and therapeutic implications. Current Psychiatry Reports, 2003, 5, 36-40.	4.5	5
32	Obsessive-Compulsive Disorder in Childhood and Adolescence. Psychopathology, 2003, 36, 55-64.	1.5	12
33	Insight en el trastorno obsesivo-compulsivo: un estudio de una muestra italiana. European Psychiatry (Ed Española), 2003, 10, 238-242.	0.0	0
34	Insight in obsessive–compulsive disorder: a study of an Italian sample. European Psychiatry, 2002, 17, 407-410.	0.2	71
35	Kleptomania: Clinical features and comorbidity in an Italian sample. Comprehensive Psychiatry, 2002, 43, 7-12.	3.1	48
36	Citalopram in refractory obsessive-compulsive disorder: an open study. International Clinical Psychopharmacology, 2001, 16, 215-219.	1.7	25

CHIARA PFANNER

#	Article	IF	CITATIONS
37	No Correlation between Aggression and Platelet ³ H-Paroxetine Binding in Obsessive-Compulsive Disorder Patients. Neuropsychobiology, 2001, 43, 117-122.	1.9	7
38	Gabapentin for Misuse of Homemade Nicotine Nasal Spray. American Journal of Psychiatry, 2001, 158, 498-498.	7.2	7
39	Pramipexole Augmentation in Panic With Agoraphobia. American Journal of Psychiatry, 2001, 158, 498-a-499.	7.2	2
40	Risperidone augmentation in refractory obsessive—compulsive disorder: an open-label study. International Clinical Psychopharmacology, 2000, 15, 297-301.	1.7	69
41	Validity and reliability of the Structured Clinical Interview for Obsessive-Compulsive Spectrum (SCI-OBS) and of the Structured Clinical Interview for Social Phobia Spectrum (SCI-SHY). International Journal of Methods in Psychiatric Research, 2000, 9, 11-24.	2.1	24
42	S03.05 Kleptomania and compulsive buying: Clinical features of an italian sample. European Psychiatry, 2000, 15, 216s-217s.	0.2	0
43	Platelet [3H]paroxetine binding in patients with OCD-related disorders. Psychiatry Research, 1999, 89, 223-228.	3.3	40
44	Immunological alterations in adult obsessive-compulsive disorder. Biological Psychiatry, 1999, 46, 810-814.	1.3	49
45	Episodic course in obsessive-compulsive disorder. European Archives of Psychiatry and Clinical Neuroscience, 1998, 248, 240-244.	3.2	71
46	Changes in Platelet Markers of Obsessive-Compulsive Patients During a Double-Blind Trial of Fluvoxamine versus Clomipramine. Pharmacopsychiatry, 1997, 30, 245-249.	3.3	29
47	The clinical impact of bipolar and unipolar affective comorbidity on obsessive–compulsive disorder. Journal of Affective Disorders, 1997, 46, 15-23.	4.1	168
48	Decreased Platelet ³ H-Paroxetine Binding in Obsessive-Compulsive Patients. Neuropsychobiology, 1996, 34, 184-187.	1.9	54
49	Comorbidity in obsessive-compulsive disorder: focus on depression. European Psychiatry, 1995, 10, 379-382.	0.2	20